ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M
ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.